I am a surgeon-scientist with a clinical practice consisting of trauma, emergency general surgery, and surgical critical care as well as a translational research focus on hemostasis and thrombosis. My basic science laboratory studies the mechanisms of trauma-induced coagulopathy (TIC) with a focus on innate immune signaling and platelet function. I am the principal investigator or co-investigator on several ongoing translational efforts in trauma and surgical care and have served as a Trans-Agency Consortium for Trauma Induced Coagulopathy (TACTIC) investigator since inception of the program. I direct the Pittsburgh Trauma and Transfusion Medicine Research Center, which is a coordinating center to leverage collaboration and resources in trauma research. I have also served as one of the directors of the Coordinating Center and the co-chair of the in-patient clinical trial committee for the NIH funded Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 (ACTIV-4) pandemic response. I serve as a mentor to numerous students, fellows, and junior faculty. My group is also co-leading a DARPA funded initiative to generate a synthetic whole blood analogue, leveraging our expertise in animal modeling and nanomedicine approaches to hemostasis. Additionally, I serve as the Chief Medical Officer of Haima Therapeutics, a biotechnology company focused on platelet-inspired therapies, highlighting my role in innovation and translational development.